Author:
Thomas Shameka P.,Keller Madison A.,Ranson Tiara,Willard Rachele E.
Abstract
AbstractAdvances in reproductive health technologies such as noninvasive prenatal testing (NIPT) are changing the landscape of prenatal care and maternal health. NIPT, made clinically available in the United States (US) in 2011, is a screening test that utilizes cell-free DNA (cfDNA) to detect for aneuploidies and genetic characteristics in fetal DNA. In September 2020, the American College of Obstetricians and Gynecologists (ACOG) recommended NIPT for all pregnant patients regardless of age or risk factors. We examined peer-reviewed, empirical studies published from January 2011 to February 2022, assessing NIPT studies with patient perspectives in the US and what is known about how empirical studies include Black women. Our scoping review draws from PubMed (with advanced MeSH search options) and Scopus databases for advanced scoping review, with 33 articles meeting our criteria. Empirical studies on NIPT show patient perceptions range across five themes: 1) accuracy / safety, 2) return of results, 3) patient knowledge, 4) informed consent, and 5) perceptions among minoritized groups (with perceptions of race and gender as a social demographic intersection). Additionally, among the 15 studies that included that Black woman in their study sample, none measured the perceptions of Black women with genetic conditions. Bridging this knowledge gap is critical because NIPT is becoming increasingly accessible across the nation and is being developed to screen for additional genetic conditions, such as sickle cell disease. Ultimately, NIPT researchers need to go to greater lengths to examine the patient perspectives of Black women with and without genetic conditions.
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology
Reference48 articles.
1. Cernat A, De Freitas C, Majid U, Trivedi F, Higgins C, Vanstone M. Facilitating informed choice about non-invasive prenatal testing (NIPT): a systematic review and qualitative meta-synthesis of women's experiences. BMC Pregnancy Childbirth. 2019;19(1):27. https://doi.org/10.1186/s12884-018-2168-4 PMID: 30642270; PMCID: PMC6332899.
2. American Society for Clinical Pathology (ASCP), 2020. “New ACOG guidelines recommend cfDNA-based NIPT for all pregnancies, not just risky ones,” Published date: Sept 23, 2020. Accessed: https://www.ascp.org/content/news-archive/news-detail/2020/09/24/new-acog-guidelines-recommend-cfdna-based-nipt-for-all-pregnancies-not-just-risky-ones.
3. Ageliki, et al. Cell-free DNA levels in pregnancies at risk of sickle cell disease and significant ethnic variation. Br J Haematol. 2006;135:738–41.
4. Campen, et al. A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies. Br J Haematol. 2020;2020(1):119–24.
5. Bianchi, Diana W. 2015. “Pregnancy: prepare for unexpected prenatal test results.” Nature, International Weekly Journal https://www.nature.com/news/pregnancy-prepare-for-unexpected-prenatal-test-results-1.17655.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献